Qiu, Su

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 660

Structure-based design of potent non-peptide MDM2 inhibitors

Ding, K., Lu, Y., Nikolovska-Coleska, Z., Qiu, S., Ding, Y., Gao, W., Stuckey, J., Krajewski, K., Roller, P. P., Tomita, Y., et al. (2005) · Journal of the American Chemical Society

Cancer-related Molecular PathwaysComputational Drug Discovery Methods

Cited by 657

Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction

Yu, S., Qin, D., Shangary, S., Chen, J., Wang, G., Ding, K., McEachern, D., Qiu, S., Nikolovska-Coleska, Z., Miller, R., et al. (2009) · Journal of Medicinal Chemistry

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 180

Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer

Shangary, S., Ding, K., Qiu, S., Nikolovska-Coleska, Z., Bauer, J. A., Liu, M., Wang, G., Lu, Y., McEachern, D., Bernard, D., et al. (2008) · Molecular Cancer Therapeutics

Cancer-related Molecular PathwaysHeat shock proteins research

Cited by 91